| Literature DB >> 33223091 |
Abstract
Increased understanding of disease pathophysiology and advances in gene therapies and drug technologies are revolutionizing treatment of muscular dystrophies and motor neuron disorders (MNDs). New drugs have been approved for Duchenne muscular dystrophy, spinal muscular atrophy, and amyotrophic lateral sclerosis. For other diseases, new targets have been identified, and new therapies are in clinical trials. The impact of such therapies will be fully understood only in the next decades. Cost burden and accessibility are major challenges in the wide application of new drugs. This article reviews advances in gene therapies, newly approved drugs, and therapeutic promises in muscular dystrophies and MNDs.Entities:
Keywords: Gene therapy; Motor neuron disorders; Muscular dystrophies; Neuromuscular diseases; Neurotherapeutics
Year: 2021 PMID: 33223091 DOI: 10.1016/j.ncl.2020.09.005
Source DB: PubMed Journal: Neurol Clin ISSN: 0733-8619 Impact factor: 3.806